Welcome to our dedicated page for Aileron Therapeutics news (Ticker: ALRN), a resource for investors and traders seeking the latest updates and insights on Aileron Therapeutics stock.
About Aileron Therapeutics Inc.
Aileron Therapeutics Inc. (NASDAQ: ALRN) is a clinical-stage biopharmaceutical company dedicated to advancing a novel pipeline of first-in-class medicines that address significant unmet medical needs in orphan pulmonary, fibrotic, and oncology indications. With a strong foundation in peptide therapeutics, Aileron is at the forefront of developing innovative therapies designed to improve patient outcomes in challenging and underserved medical conditions.
Core Product Pipeline
LTI-03: Aileron's lead product candidate, LTI-03, is a synthetic peptide with a dual mechanism of action targeting alveolar epithelial cell survival and inhibition of profibrotic signaling. Currently in clinical development, LTI-03 has shown promise in treating idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. The therapy's unique approach aims to not only slow disease progression but potentially restore healthy lung function.
LTI-01: Another key asset in Aileron's pipeline, LTI-01, is a proenzyme developed for loculated pleural effusions. Having completed Phase 1b and Phase 2a clinical trials, LTI-01 has received Orphan Drug Designation in both the U.S. and EU, as well as Fast Track Designation in the U.S., underscoring its potential to address critical unmet needs in this condition.
ALRN-6924: Previously a lead oncology candidate, ALRN-6924 is a clinical-stage therapy that reactivates the tumor-suppressing protein p53 by targeting MDMX and MDM2. This innovative approach has positioned ALRN-6924 as the first and only clinical-stage drug targeting MDMX, with potential applications in rare cancers like retinoblastoma.
Market Position and Competitive Edge
Aileron Therapeutics operates in the highly specialized fields of peptide-based therapeutics and orphan disease indications. By focusing on first-in-class therapies, the company differentiates itself from competitors through its innovative mechanisms of action and targeted approach to high-need patient populations. Its strategic focus on orphan diseases, supported by Orphan Drug and Fast Track designations, positions it to capitalize on regulatory incentives and market exclusivity.
Industry Significance
As a pioneer in peptide therapeutics, Aileron Therapeutics is contributing to the advancement of treatments for complex diseases with limited existing options. Its commitment to addressing unmet medical needs in IPF, fibrosis, and oncology aligns with broader industry trends emphasizing innovation in rare and life-threatening diseases. With a robust clinical pipeline and a focus on leveraging cutting-edge science, Aileron is poised to make a meaningful impact on patient care and the biopharmaceutical landscape.
Aileron Therapeutics (NASDAQ:ALRN) has initiated a Phase 1b trial of ALRN-6924 in patients with advanced p53-mutated non-small cell lung cancer (NSCLC). The trial will enroll 60 patients, with results expected in mid-2022. Aileron also plans to present final data from a completed Phase 1b trial for small cell lung cancer (SCLC) at scientific meetings in late 2021. As of June 30, 2021, the company reported $59.5 million in cash, expected to fund operations into 2023. R&D expenses rose to $3.9 million, contributing to a net loss of $5.7 million for Q2 2021.
Aileron Therapeutics (NASDAQ:ALRN) announced that its CEO, Manuel Aivado, will participate in a fireside chat at the William Blair Biotech Focus Conference 2021 on July 15, 2021, at 3:00 p.m. ET. Virtual 1x1 meetings will be held from July 14-15. A webcast of the chat will be available on Aileron’s website, with a replay archived for 30 days. Aileron focuses on improving chemotherapy experiences for cancer patients, specifically targeting those with p53-mutated cancers using its lead product, ALRN-6924, which aims to reduce chemotherapy-related side effects.
Aileron Therapeutics (Nasdaq: ALRN) has initiated a Phase 1b trial for ALRN-6924, targeting 60 patients with advanced p53-mutated non-small cell lung cancer (NSCLC) undergoing chemotherapy. This randomized, double-blind, placebo-controlled trial will assess treatment cycles free of severe toxicities and the impact on patients' quality of life. The first interim safety data is expected by late 2021, with final results anticipated in mid-2022. Aileron aims to utilize ALRN-6924 as a chemoprotective agent to selectively shield healthy cells while allowing the chemotherapy to target cancer cells, addressing a significant need for cancer patients.
Aileron Therapeutics (NASDAQ:ALRN) announced its inclusion in the Russell Microcap® Index, effective June 28, 2021. This membership lasts for one year and grants automatic inclusion in relevant growth and value style indexes, which can potentially broaden its investor base. Aileron focuses on chemoprotection oncology, developing ALRN-6924, a dual inhibitor aimed at protecting healthy cells during chemotherapy. With nearly 1 million p53-mutated cancer diagnoses annually in the U.S., the company addresses a significant medical need.
Aileron Therapeutics (NASDAQ:ALRN) will host a fireside chat on May 26, 2021, at 11:00 am ET, focusing on the chemoprotection of cancer patients from chemotherapy-induced toxicities. Moderated by Soumit Roy, Ph.D., the event will feature hematologist Alan List, M.D., and geriatric oncologist Lodovico Balducci, M.D. They will discuss the need for chemoprotection and its potential to improve patients' quality of life. Aileron's ALRN-6924, a dual MDM2/MDMX inhibitor, is in development to provide selective chemoprotection for patients with p53-mutated cancers, impacting nearly 50% of cancer patients.
Aileron Therapeutics (NASDAQ:ALRN) announced key developments regarding ALRN-6924, targeting p53-mutated non-small cell lung cancer (NSCLC). The company plans to initiate a Phase 1b trial in Q2 2021, with interim results expected by year-end. Aileron aims to enhance chemotherapy tolerability through selective chemoprotection, potentially improving patients' quality of life. Financially, Aileron raised $55.7 million in Q1 2021, enhancing its cash position to $63.4 million. Despite a net loss of $7.0 million, the company expects this funding to extend operations into late 2023.
Aileron Therapeutics (NASDAQ:ALRN) reported significant progress in 2020, focusing on chemoprotection for cancer patients with p53 mutations. The company achieved clinical proof-of-concept in its Phase 1b trial for ALRN-6924 in small cell lung cancer (SCLC) and is set to initiate a new Phase 1b trial for ALRN-6924 in advanced non-small cell lung cancer (NSCLC) in Q2 2021. The company raised $55.7 million in early 2021, with a cash position of $13.8 million as of December 31, 2020, expected to fund operations into late 2023, indicating strong financial support for ongoing trials.
Aileron Therapeutics (NASDAQ:ALRN) announced that CEO Manuel Aivado will present at the 2021 H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will highlight the Phase 1b trial of ALRN-6924 for advanced p53-mutated non-small cell lung cancer, set to begin in Q2 2021. Aileron's innovative approach aims to protect healthy cells from chemotherapy without hindering its efficacy against cancer cells, potentially enhancing patient quality of life. A webcast will be available for replay on Aileron’s website after the event.
Aileron Therapeutics (Nasdaq: ALRN) plans to expand enrollment in its Phase 1b clinical trial of ALRN-6924, targeting 60 patients with advanced p53-mutated non-small cell lung cancer (NSCLC), up from 40. This trial aims to determine the efficacy of ALRN-6924 in reducing chemotherapy-induced side effects while preserving treatment effectiveness. Initial data is expected by late 2021, with full results by mid-2022. The recent FDA approval of a chemoprotective agent paves the way for ALRN-6924, a biomarker-based approach designed to protect healthy cells during chemotherapy.
Aileron Therapeutics (Nasdaq: ALRN) announced a registered direct offering of 32,630,983 shares of common stock at $1.10 each, with an expected gross proceeds of $35.9 million. The offering is anticipated to close around January 8, 2021, subject to customary conditions. Funds from this offering will be directed towards the clinical development of ALRN-6924, aimed at providing chemoprotection for patients undergoing chemotherapy, along with general working capital. The shares are offered under a shelf registration statement with the SEC.
FAQ
What is the current stock price of Aileron Therapeutics (ALRN)?
What is the market cap of Aileron Therapeutics (ALRN)?
What does Aileron Therapeutics Inc. specialize in?
What are Aileron's key product candidates?
How does LTI-03 work?
What regulatory designations has Aileron received?
What differentiates Aileron from its competitors?
What is ALRN-6924, and what does it target?
What is idiopathic pulmonary fibrosis (IPF)?
What are the risks associated with Aileron's clinical programs?
